Who is sponsoring NCT04894318?

NCT04894318 is sponsored by TC Erciyes University.

What drugs are being tested in NCT04894318?

Interventions in NCT04894318: Low-fat and low-cholesterol diet.

What condition does NCT04894318 study?

NCT04894318 studies Dyslipidemias.

Is NCT04894318 still recruiting?

NCT04894318 is currently completed. Last updated 20 May 2021.

Last reviewed 2021-05-20 · How we verify

NCT04894318

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Effect Of Low-Fat And Low-Cholesterol Dietary Intervention On LDL Sub-Groups In Turkısh Dyslipidemic Patients

Completed NA Last updated 20 May 2021

What this trial tests

NA trial testing Low-fat and low-cholesterol diet in Dyslipidemias in 47 participants. Completed in 25 July 2019.

Timeline

5 September 2017

Primary endpoint
5 September 2018

25 July 2019

Quick facts

Lead sponsor	TC Erciyes University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	supportive care
Enrollment	47
Start date	5 September 2017
Primary completion	5 September 2018
Estimated completion	25 July 2019
Sites	1 location across Turkey (Türkiye)

Drugs / interventions tested

Low-fat and low-cholesterol diet

Conditions studied

Dyslipidemias — all drugs for Dyslipidemias →

Sponsor

TC Erciyes University

Who can join

Adults 25 to 65, any sex, with Dyslipidemias. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study is to compare LDL sub-group concentration before and after a diet with low-fat and low-cholesterol prescribed to dyslipidemic patients for 12 weeks.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Dyslipidemias

Currently open trials in the same condition.

NCT07308314 — Taining Golden Lake Comprehensive Chronic Disease Management Initiative · recruiting
NCT06526273 — PILI 'Āina Household · NA · recruiting
NCT06797401 — Phase 2 Trial Evaluating the Efficacy and Safety of RBD5044 in Patients With Mixed Dyslipidemia · Phase 2 · recruiting
NCT06380322 — Military Health and Nutrition Examination Study · recruiting
NCT06183307 — Effects of Nattokinase on Inflammation and Cardiovascular Risk Markers in Patients With Dyslipidemia · NA · recruiting

Other TC Erciyes University trials

Trials by the same sponsor.

NCT07007858 — Effects of High-Velocity Passive Stretch on Spasticity, Function, and Muscle Structure in Spastic CP Children · NA · enrolling by invitation
NCT07529964 — MMP-2/3 and Periapical Healing Outcomes · not yet recruiting
NCT07526831 — Comparison of the Analgesic Efficacy of Adductor Canal Block and Combined Adductor Canal Block Plus IPACK Block in Knee · recruiting
NCT07371806 — EFFETCS OF MİNDFULNESS-BASED STRESS REDUCTION İN WOMEN WİTH CORONARY ARTERY DİSEASE · NA · not yet recruiting
NCT07499947 — Predicting Spinal Hypotension in Cesarean Section · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04894318 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by TC Erciyes University
Last refreshed: 20 May 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04894318.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing